BIOPHARMA
By
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus in the Race for Oral GLP-1 Leadership?
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its…
Is Johnson & Johnson’s $1 Billion Pennsylvania Investment a Defining Bet on the Future of Cell Therapy?
New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1 billion to construct…
Is Johnson & Johnson Preparing to Divest DePuy Synthes in a $20 Billion Strategic Pivot Toward Pharmaceuticals?
Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is reportedly exploring a…
Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular Targets with AI-Designed Macrocyclic Peptides?
Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration and licensing agreement…
Biotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race
The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…
China Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?
China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…
